10.00Open10.00Pre Close0 Volume7 Open Interest68.00Strike Price0.00Turnover135.89%IV2.08%PremiumDec 20, 2024Expiry Date8.41Intrinsic Value100Multiplier4DDays to Expiry1.59Extrinsic Value100Contract SizeAmericanOptions Type0.8195Delta0.0248Gamma8.00Leverage Ratio-0.3788Theta0.0055Rho6.56Eff Leverage0.0205Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
No comment yet